Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Bevacizumab Biosimilar IBI305
The First People's Hospital of Lianyungang
Post-orthotopic Liver Transplantation
1 trial -
Bevacizumab combined with Oxaliplatin and TAS-102
The First People's Hospital of Lianyungang
Advanced Colorectal Cancer
1 trial -
Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Bexmarilimab
Lacuna Pharma Pty Ltd
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
1 trial -
Bicalutamide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Neoplasms
1 trial -
BinD19
The First People's Hospital of Lianyungang
Relapsed B-cell Acute Lymphoblastic Leukemia
1 trial -
Bispecific antibody-based combined with CAR-T cell therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
B-cell Non-Hodgkin Lymphoma
1 trial -
Bisphosphocin Nu-3
Lakewood-Amedex Biotherapeutics
Diabetic Foot Infections
1 trial -
Bivalent killed oral cholera vaccine
International Peace Maternity and Child Health Hospital
Cholera
1 trial -
Bleomycin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lymphatic Malformation
1 trial -
Blinatumomab
The First People's Hospital of Lianyungang
B-cell Acute Lymphoblastic Leukemia
1 trial -
Blinatumomab plus Reduced-dose Chemotherapy
The First People's Hospital of Lianyungang
Precursor B-Cell Acute Lymphoblastic Leukemia
1 trial -
Bone marrow derived stem cells
Neuroscience Trials Australia
Spinal Cord Injury
1 trial -
Bortezomib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
Bortezomib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Plasma Cell Leukemia
1 trial -
Bosentan
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Bovine colostrum
Hospital Authority, Hong Kong
Severe Alcoholic Hepatitis in 'Extremis'- Defined by mDF>54
1 trial -
Bozitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC
1 trial -
Briquilimab
Jasper Therapeutics
Chronic Spontaneous Urticaria
1 trial -
Briquilimab
Jasper Therapeutics
Chronic Inducible Urticaria
1 trial -
Briquilimab
Jasper Therapeutics
Urticaria Chronic
1 trial -
Briquilimab
Jasper Therapeutics
Chronic Urticaria
1 trial -
Bronchial basal cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Bronchiectasis
1 trial -
Bronchial basal cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chronic Obstructive Pulmonary Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources